These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

70 related items for PubMed ID: 11896466

  • 1. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway.
    Fuerer C, Iggo R.
    Gene Ther; 2002 Feb; 9(4):270-81. PubMed ID: 11896466
    [Abstract] [Full Text] [Related]

  • 2. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
    Fuerer C, Homicsko K, Lukashev AN, Pittet AL, Iggo RD.
    BMC Cancer; 2006 Oct 04; 6():236. PubMed ID: 17020613
    [Abstract] [Full Text] [Related]

  • 3. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway.
    Brunori M, Malerba M, Kashiwazaki H, Iggo R.
    J Virol; 2001 Mar 04; 75(6):2857-65. PubMed ID: 11222711
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells.
    Chen RH, McCormick F.
    Cancer Res; 2001 Jun 01; 61(11):4445-9. PubMed ID: 11389074
    [Abstract] [Full Text] [Related]

  • 6. Replicating parvoviruses that target colon cancer cells.
    Malerba M, Daeffler L, Rommelaere J, Iggo RD.
    J Virol; 2003 Jun 01; 77(12):6683-91. PubMed ID: 12767988
    [Abstract] [Full Text] [Related]

  • 7. Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters.
    Gustavson MD, Crawford HC, Fingleton B, Matrisian LM.
    Mol Carcinog; 2004 Nov 01; 41(3):125-39. PubMed ID: 15457508
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL.
    Cancer Res; 2003 Apr 01; 63(7):1490-9. PubMed ID: 12670895
    [Abstract] [Full Text] [Related]

  • 10. Cross-talk between Rac1 GTPase and dysregulated Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-mediated transcriptional activation.
    Esufali S, Bapat B.
    Oncogene; 2004 Oct 28; 23(50):8260-71. PubMed ID: 15377999
    [Abstract] [Full Text] [Related]

  • 11. Identification of SP5 as a downstream gene of the beta-catenin/Tcf pathway and its enhanced expression in human colon cancer.
    Takahashi M, Nakamura Y, Obama K, Furukawa Y.
    Int J Oncol; 2005 Dec 28; 27(6):1483-7. PubMed ID: 16273202
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor.
    Dong YF, Soung do Y, Schwarz EM, O'Keefe RJ, Drissi H.
    J Cell Physiol; 2006 Jul 28; 208(1):77-86. PubMed ID: 16575901
    [Abstract] [Full Text] [Related]

  • 14. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways.
    Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC.
    Cancer Res; 2003 Feb 01; 63(3):728-34. PubMed ID: 12566320
    [Abstract] [Full Text] [Related]

  • 15. The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer.
    González-Sancho JM, Aguilera O, García JM, Pendás-Franco N, Peña C, Cal S, García de Herreros A, Bonilla F, Muñoz A.
    Oncogene; 2005 Feb 03; 24(6):1098-103. PubMed ID: 15592505
    [Abstract] [Full Text] [Related]

  • 16. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas.
    Schwartz DR, Wu R, Kardia SL, Levin AM, Huang CC, Shedden KA, Kuick R, Misek DE, Hanash SM, Taylor JM, Reed H, Hendrix N, Zhai Y, Fearon ER, Cho KR.
    Cancer Res; 2003 Jun 01; 63(11):2913-22. PubMed ID: 12782598
    [Abstract] [Full Text] [Related]

  • 17. The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma.
    Shiina H, Igawa M, Breault J, Ribeiro-Filho L, Pookot D, Urakami S, Terashima M, Deguchi M, Yamanaka M, Shirai M, Kaneuchi M, Kane CJ, Dahiya R.
    Clin Cancer Res; 2003 Jun 01; 9(6):2121-32. PubMed ID: 12796377
    [Abstract] [Full Text] [Related]

  • 18. Identification of Tcf-4 as a transcriptional target of p53 signalling.
    Rother K, Johne C, Spiesbach K, Haugwitz U, Tschöp K, Wasner M, Klein-Hitpass L, Möröy T, Mössner J, Engeland K.
    Oncogene; 2004 Apr 22; 23(19):3376-84. PubMed ID: 14990988
    [Abstract] [Full Text] [Related]

  • 19. Identification of MYCBP as a beta-catenin/LEF-1 target using DNA microarray analysis.
    Jung HC, Kim K.
    Life Sci; 2005 Jul 29; 77(11):1249-62. PubMed ID: 15979100
    [Abstract] [Full Text] [Related]

  • 20. Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway.
    Dvory-Sobol H, Sagiv E, Liberman E, Kazanov D, Arber N.
    Cancer; 2007 Jan 15; 109(2):188-97. PubMed ID: 17149756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.